Alveltamig
Alveltamig (ZG006) is a trispecific anti-T cell engager (Tri-TE) targeting Delta-like ligand 3 (DLL3) and CD3. Alveltamig has two distinct DLL3 epitopes, and bridges tumor cells and T cells by strongly binding to DLL3 on tumor cells and CD3 on T cells, thereby mediating T cell-specific killing of DLL3-expressing tumor cells. Alveltamig can be used for the study of small cell lung cancer (SCLC) or neuroendocrine carcinoma (NEC) [1].
Product Specifications
Product Name Alternative
ZG006
UNSPSC
12352005
Target
CD3
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[Alveltamig]
References & Citations
[1]Qiming Wang, et al. A phase 1 dose escalation and expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma. Journal of Clinical Oncology. Volume 43, Number 16_suppl.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
